ClinicalTrials.gg
RecruitingNCT06379425Updated Oct 5, 2026

Impact of Preoperative Opioid-free Multimodal Analgesia on Time to Trial of Void in Ambulatory Urogynecologic Surgeries

A Phase 4 interventional study of Acetaminophen and Celecoxib in Pain, Postoperative and Postoperative Pain, Acute, sponsored by Northwell Health. Recruiting at 1 site in United States. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Northwell Health · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.
Updated Oct 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
70
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing celecoxib in Pain, Postoperative — 2 open to participants now, 2 under way, none of them phase 3. Celecoxib · Pain, Postoperative.

Planned enrollment
14th of 19
70 · median 132
Started
2024
the only one that year
Phase 4
5 of 19
1 open now
Registered
18th of 19
by date

Among the 19 studies testing celecoxib in Pain, Postoperative, this one is the 14th largest by planned enrollment, is the only one that started in 2024, is one of 5 in phase 4, and was the 18th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

2 of the 19 studies testing celecoxib in Pain, Postoperative are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About celecoxib

Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing celecoxib in Pain, Postoperative, or all of them as a file.
02

Study summary

This is a double-arm randomized control trial evaluating the impact of preoperative opioid-free analgesia on time to trial of void in ambulatory urogynecologic surgeries. The investigators hypothesize that receipt of acetaminophen, celecoxib and gabapentin preoperatively versus acetaminophen alone will reduce the time to trial of void in patients undergoing same-day minor urogynecologic procedures.

03

Conditions studied

  • Pain, Postoperative
  • Postoperative Pain, Acute

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. All female patients over 18 years of age from the Northwell Health urogynecology offices in Bay Shore, Syosset, and Huntington, NY who are undergoing transvaginal minor urogynecologic surgery (midurethral sling, periurethral bulking injections, anterior repair, posterior repair, and perineorrhaphy) at South Shore Surgery Center
  4. In good general health as evidenced by medical history
  5. Ability to take oral medication and be willing to adhere to the study intervention
  6. Patients may be English or Spanish-speaking and must be able to provide informed consent

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy or lactation
  2. Younger than age 18
  3. Known allergic reactions to acetaminophen, celecoxib or gabapentin or any components within the medication formulation
  4. Patients with Myasthenia Gravis, renal disease with \< 50, seizure disorder, substance use disorder, anaphylaxis and angioedema to gabapentin, Drug reaction with Eosinophilia and Systemic Symptoms (DRESS), driving impairment, increased seizures suicidal behavior and respiratory depression.
  5. Patients with a , history of asthma, urticaria, or other allergic type reactions after taking aspirin or other NSAIDS or DRESS, history of gastric bypass surgery, heart failure, active GI ulcer, active GI bleeding, inflammatory bowel disease, cerebrovascular bleeding, liver impairment/hepatic disease, hyperkalemia.
  6. Patients with compromised renal function who are notable to receive NSAIDs
  7. Patients with significant cardiovascular disease, such as patients with heart failure
  8. Patient with recent evidence of worsening fluid retention
  9. Both non-English and non-Spanish speaking patients
  10. Urogynecologic surgeries for apical repair (sacrocolpopexy, uterosacral ligament suspension, sacrospinous ligament suspension, colpocleisis)
  11. Current use of illicit substances (cocaine, non-prescription opioids, marijuana)
  12. Current use of gabapentin as home medication
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Standard of Care (SOC) (acetaminophen)

    one time dose of 1000mg acetaminophen orally

    Drug: Acetaminophen

  • Experimental
    Standard of Care (SOC) (acetaminophen) and investigational product (celecoxib + gabapentin)

    one time dose of 1000mg acetaminophen orally combined with 400mg celecoxib orally, and 300mg gabapentin orally

    Drug: Acetaminophen · Drug: Celecoxib · Drug: Gabapentin

Interventions

  • Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery

  • Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery

  • Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery

06

What researchers measure

Primary outcomes

  1. Time to initiation of active trial of void

    Time frame: through study completion, an average of 2 years

07

Study locations

1 of 1 sites recruiting
  • Northwell Health South Shore Surgery Center
    Bay Shore, New York 11706, United States
    Recruiting
    • Kathleen R Catalano, MSN, RN-BC · Contactkcatalano@southshoresurg.com · 631-647-5550
    • Nirmala Pillalamarri, MD · Principal investigator
    • Steliana Fakas, MD · Sub investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jan 2027, 34 months after the start.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 34 months is above that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Mar 2026 → Jan 2027 and completion Mar 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2024
First posted
Apr 23, 2024
StartActual
Mar 1, 2024
Primary completionEst.
Jan 1, 2027was Mar 2026
CompletionEst.
Mar 1, 2027was Mar 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 1, 2026→Jan 1, 2027
Oct 5, 2026
Study completion
Mar 1, 2026→Mar 1, 2027
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Primary completion Mar 1, 2026→Jan 1, 2027
    Study completion Mar 1, 2026→Mar 1, 2027
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06379425
Lead sponsor
Northwell Health
Responsible party
Sponsor
First posted
Apr 23, 2024
Start date
Mar 1, 2024
Primary completion
Jan 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Oct 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Celecoxib · Gabapentin

Start the discussion